WO – Drug Approvals International

Pexidartinib, New Patent, WO 2017215521, Crystal Pharmatech Co Ltd

Pexidartinib, New Patent, WO, 2017215521, Crystal Pharmatech Co Ltd (WO2017215521) PLX3397 HYDROCHLORIDE CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017215521 CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD INVENTORS CHEN, Minhua; (CN). ZHANG, Yanfeng; (CN). ZOU, Po; (CN). ZHANG, Xiaoyu; (CN) Novel crystalline forms of PLX3397 hydrochloride (designated as Forms CS2 and CS3), processes for their preparation …

QUILSECONAZOLE, VT 1129, New Patent, WO, 2017049080, Viamet

VT 1129 BENZENE SULFONATE CAS 1809323-18-9 VT 1129 1340593-70-5 CAS MF C22 H14 F7 N5 O2, MW 513.37 2-Pyridineethanol, α-(2,4-difluorophenyl)-β,β-difluoro-α-(1H-tetrazol-1-ylmethyl)-5-[4-(trifluoromethoxy)phenyl]-, (αR)- R ISOMER ROTATION + QUILSECONAZOLE, VT-1129 Viamet, in collaboration with Therapeutics for Rare and Neglected diseases, is investigating quilseconazole benzenesulfonate (VT-1129), a small-molecule lanosterol demethylase (CYP51) inhibitor, developed using the company’s Metallophile technology, for treating fungal …